O(6)-Methylguanine-DNA Methyltransferase
"O(6)-Methylguanine-DNA Methyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that transfers methyl groups from O(6)-methylguanine, and other methylated moieties of DNA, to a cysteine residue in itself, thus repairing alkylated DNA in a single-step reaction. EC 2.1.1.63.
| Descriptor ID |
D019853
|
| MeSH Number(s) |
D08.811.913.555.500.800.650
|
| Concept/Terms |
O(6)-Methylguanine-DNA Methyltransferase- O(6)-Methylguanine-DNA Methyltransferase
- Methylated-DNA-Protein-Cysteine S-Methyltransferase
- Methylated DNA Protein Cysteine S Methyltransferase
- S-Methyltransferase, Methylated-DNA-Protein-Cysteine
- O(6)-Methylguanine Methyltransferase
- O(6)-Alkylguanine-DNA Alkyltransferase
- O(6)-MeG-DNA Methyltransferase
- O(6)-Methylguanine DNA Transmethylase
- Guanine-O(6)-Alkyltransferase
- O(6)-AGT
|
Below are MeSH descriptors whose meaning is more general than "O(6)-Methylguanine-DNA Methyltransferase".
Below are MeSH descriptors whose meaning is more specific than "O(6)-Methylguanine-DNA Methyltransferase".
This graph shows the total number of publications written about "O(6)-Methylguanine-DNA Methyltransferase" by people in this website by year, and whether "O(6)-Methylguanine-DNA Methyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "O(6)-Methylguanine-DNA Methyltransferase" by people in Profiles.
-
Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT. Radiother Oncol. 2021 04; 157:234-240.
-
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer. 2011 Sep 06; 105(6):773-7.
-
DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012 Jun; 51(6):491-9.
-
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.
-
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009 Dec; 11(6):825-32.
-
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42.
-
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):549-53.
-
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15; 67(24):11499-504.
-
Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev. 2006; 30(3):284-91.
-
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.